cassava sciences' phase 3 results

Initiation of a Phase 3 trial remains on schedule for 2nd half 2021. Cassava Sciences Alz. Drug got extremely positive test ... Source: Interactive Brokers Analyst Jason McCarthy of Maxim raised SAVA to a buy with a target of $14 after promising phase 2 results for sumifilam, a drug to treat Alzheimer's. Barbier says that Cassava hopes to begin the phase 3 study by the end of 2021. Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the third quarter ended September 30, 2021.Net . . This was announced in an official press release by the company on its website. Cassava Sciences Alz. Apparent False and/or Misstatements in Cassava's Phase 3 SPA Request On August 24, 2021, Cassava Sciences announced "Agreement with the FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Cassava Sciences - Get Cassava Sciences, Inc. Report said Wednesday it had begun an initial Phase 3 study of the drugmaker's Alzheimer's treatment candidate simufilam. This Phase 2b study will also be funded by NIH. (SAVA) - Cassava Sciences Kickstarts Second Late-Stage ... We've crossed the Rubicon." In addition, Cassava Sciences' second Phase 3 study is designed to evaluate symptomatic improvement in Alzheimer's disease. Cassava Sciences Inc. (SAVA) full year performance was 3292.00% Cassava Sciences outlines Pivotal Phase 3 trial design for ... Clinic visits will occur 4 weeks after the baseline . It is a debt-free company. A key objective of the Phase 2b study will be to replicate the beneficial effects of PTI-125 on biomarkers of Alzheimer's disease in a larger, blinded study. Cassava shares are up nearly 210% (at one point, the stock was up over . Bik . Cassava Sciences plans to launch two Phase 3 clinical trials evaluating the efficacy of simufilam, its investigational oral treatment for Alzheimer's disease, in the second half of this year, the company announced.. The company's scientists presented the new data during an oral presentation today at the International Conference on Clinical Trials on . AUSTIN, Texas, June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced the selection of Premier Research International as its clinical research organization (CRO) to help conduct the Phase 3 clinical program of simufilam for Alzheimer's disease. Cassava Sciences Has Value and Is Likely To Proceed to Phase 3 Why Shares of Cassava Sciences Rose 15% Today | The Motley ... Why Might Cassava Succeed With Its Alzheimer's Drug, When ... In addition to sumifilam, Cassava Sciences is also working on developing a diagnostic test for Alzheimer's disease. Cassava Jumps on Plan for Phase 3 Trial of Alzheimer's Drug Cassava Sciences in the second half plans to start a six-month double-blind Phase 3 study of its Alzheimer's-treatment candidate, simufilam. Investors will primarily focus on updates on its lead drug candidate when it reports results. . Drug got extremely positive test results.and then kicked to the curb! While the company is small, its science has been partially funded by the National Institutes of . ; The second Phase 3 study is designed to evaluate the safety and . In fact, one author recently called SAVA stock a "volatile, battleground stock." This is because the company has endured a number of short attacks recently. AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company's investigational drug for patients with Alzheimer's disease. Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, announced today it has initiated an initial Phase 3 efficacy study of simufilam, the Company's . Cassava Sciences' Phase 2b study of sumifilam in Alzheimer's disease was funded by clinical research grant #AG060878 from the National Institutes of Health (NIH/NIA). Advisor Insights; Personal Finance; Market Volatility; Retirement Planning; Start Investing; Save for College; Best Investments; See All . Next Steps Cassava Sciences believes today's data and prior clinical results support advancing simufilam into a Phase 3 clinical program in Alzheimer's disease. Cassava Sciences, like many other biotech stocks, is a very volatile stock. The SPAs document that FDA has reviewed and agreed upon the key design features of Cassava Sciences' Phase 3 study protocols. Cassava Sciences believes today's data and prior clinical results support advancing simufilam into a Phase 3 clinical program in Alzheimer's disease. Cassava Sciences' Phase 3 efficacy studies of simufilam in Alzheimer's disease are being conducted under Special Protocol Assessments (SPA) from the U.S. Food and Drug Administration (FDA . ET - AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2021.Net loss for the second quarter ended June 30, 2021, was $5.1 million, or $0.13 per share, compared to a net loss of $1 . Cassava Sciences, Inc. . Approximately 750 participants will be randomized (1:1) to receive either placebo or 100 mg tablets of simufilam, twice daily, for 52 weeks. Cassava Sciences plans to initiate phase 3 trials in the second half of 2021, with "two double-blind, randomized, placebo-controlled studies in patients with mild-to-moderate Alzheimer's disease . Shares of the Austin company at last check were down 3.8% to $55.01. The content of this press release is solely the responsibility of Cassava Sciences and does not necessarily represent the official views of the NIH/NIA. Cassava Sciences (SAVA) has initiated a second Phase 3 study of simufilam, an investigational drug for patients with Alzheimer's disease ((AD)).Shares up 3.5% premarket at $48.89.The. The company recently announced positive results of the drug in a Phase 2 study and plans to launch Phase 3 clinical trials in the second half of 2021. Just as Cassava reported good clinical results, Anavex announced on July 29 that Anavex 2-73 prevented cognitive deficits in an animal model. Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease. The goal is to demonstrate a slower rate of decline in cognition and . Based on the preliminary results, Cassava Sciences said it remains on track to initiate a Phase 3 trial for simufilam in the second half of 2021. Cassava Sciences Inc (NASDAQ: SAVA) is rocketing in the market this morning, and for good reason.The company announced the completion of an End-of-Phase 2 meeting with the FDA and will be moving . SAVA recent financial results announcement. Shares of Cassava Sciences Inc. SAVA, -0.90% more than doubled toward a near 10-year high in very active trading Tuesday, after the company focused on neurodegenerative disease treatments . Initiation of a Phase 3 trial remains on . This second Phase 3 study is designed to evaluate the safety and efficacy of simufilam over 78 weeks in approximately 1,000 patients . AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company . Cassava Sciences plans to initiate phase 3 trials this fall for simufilam, with "two double-blind, randomized, placebo-controlled studies in patients with mild-to-moderate Alzheimer's disease . Alzheimer's disease is a very difficult disease to navigate through for both the patients and their families. Cassava holds cash equivalents and a cash balance of $25.3 million by the end of Q2 2020. Shares of Cassava Sciences . Cassava Sciences' pivotal Phase 3 clinical program consists of two double-blind, randomized, placebo-controlled studies, each described below. SAVA special agreement with FDA. Consistent with previous guidance, Cassava Sciences plans . Cassava, in sharp contrast, is starting its phase 3 trial in Alzheimer's patients later this year. Neurodegenerative disease focused clinical-stage biopharmaceutical company Cassava Sciences Inc. (SAVA:NASDAQ), today announced additional positive clinical data from a Phase 2a study of PTI-125, its investigational Alzheimer's disease drug candidate. Cassava Sciences, Inc. (SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company s investigational drug for patients with Alzheimer s disease. Westend61/ Shares of Cassava Sciences jumped as much as 16% on Monday on news that it successfully completed an end-of-phase two meeting with the FDA for its Alzheimer's treatment Simufilam. Cassava Sciences (NASDAQ: SAVA), the Alzheimer's disease (AD) drug company, certainly has had a rough time. We believe the underlying science is solid, the drug appears safe and the clinical roadmap makes sense. when it's clinical test results were not nearly as good as Cassava's new AD drug, 'Simufilam' tests results. AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company's investigational drug for patients with Alzheimer's disease.This second Phase 3 study is designed to evaluate the safety and efficacy of simufilam over 78 weeks in approximately 1,000 patients with . Quanterix Corp. QTRX, 6.88% said that while it was previously engaged by Cassava Sciences Inc. SAVA, -21.79% to perform sample testing, the digitized biomarker analysis company said it, or its employees, "did not interpret the test results or prepare the data charts" presented by Cassava to the Alzheimer's Association International Conference . Cassava Sciences' first Phase 3 study is designed to evaluate disease-modifying effects of simufilam in Alzheimer's disease. Based on these positive Phase 2a results, Cassava Sciences plans to initiate a Phase 2b study of PTI-125. Aug 3 (Reuters) - Cassava Sciences Inc <SAVA.O>::CASSAVA SCIENCES REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.13.Q2 EARNINGS PER SHARE ESTIMATE $-0.13 -- REFINITIV IBES DATA . Cassava, in sharp contrast, is starting its phase 3 trial in Alzheimer's patients later this year. 2/3 — Cassava Sciences (@CassavaSciences) August 4, 2021. Cassava Sciences daily chart since Nov. 2019. SAVA . Being Patient sat down with Cassava Sciences President and CEO Remi Barbier to discuss the ins and outs of the research in simufilam and why Alzheimer's is such a challenging disease to tackle. PTI-125 is a small molecule that targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer's brain. SAVA stock is up over 1,050% this year based on the potential for Simufilam to be an effective Alzheimer's disease . Cassava, which announced the study in February, said the initial Phase 3 study is designed to . ET Cassava Sciences stock drops 6.7% premarket, after plunging 59.0% over the past 3 weeks Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm finance.yahoo.com - December 3 at 10:51 PM: While Cassava Sciences Is a Risky Play, It Has Substantial Payoff Potential investorplace.com - December 3 at 2:03 PM Cassava is comparing results to a 2010 study of Alzheimer's patients that did include a placebo cohort. Allegations questioning the 'accuracy and integrity' of data from Cassava Sciences' (NASDAQ:SAVA) Phase-3 clinical studies for Simufilam, its Alzheimer treatment, surfaced on Aug. 25. Phase 3 Detailed Description: The primary objective of this study is to investigate the safety and efficacy of simufilam (PTI-125) in enhancing cognition and slowing cognitive and functional decline following 76-week, repeat-dose oral administration in participants with mild-to-moderate AD. Cassava Sciences (SAVA), a clinical-stage emerging biopharma venture focusing on neuroscience, reported initiation of a phase 2b study of its lead candidate, PTI-125 in Alzheimer's patients. In 2017, Cassava Sciences started with a Phase 1 safety study of 50, 100, or 200 mg of PTI-125 in 24 healthy adults. These elements are critical to ensure that Cassava Sciences' planned Phase 3 studies of simufilam in Alzheimer's disease can be considered adequate and well-controlled studies in support of a . Journal considers 'expression of concern' for 2005 Cassava Sciences paper it published Seeking Alpha - 11/22/2021 3:13:10 PM: Pharma dealmaking, Cassava Sciences, Clover Health among healthcare headliners this week Seeking Alpha - 11/20/2021 9:00:42 PM: Cassava Sciences launches second Phase 3 study of simufilam in Alzheimer's Disease Seeking Alpha - 11/18/2021 9:29:51 AM Cassava Sciences Inc (NASDAQ:SAVA) reported a net loss of $1.1 million in Q2 2020.The company expects to use $5 million in 2020 for its operations. However, with positive 9-month reports and the possibility of a phase 3 trial, the company has a lot of room to grow. Cassava Sciences Inc (NASDAQ: SAVA) announced an agreement with the FDA under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 trials for oral simufilam in treating Alzheimer's . A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks. The second Phase 3 study in 1,000 patients, called REFOCUS-ALZ, will evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 78 weeks. Related: Cassava Sciences' Simufilam Data . The goal is to demonstrate improved cognition and health function in subjects . Cassava Sciences ( SAVA) - Get Cassava Sciences, Inc. Report said Wednesday it had begun an initial Phase 3 study of the drugmaker's Alzheimer's treatment candidate simufilam. Shares of the Austin company . AUSTIN, Texas, June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced the selection of Premier Research International as its clinical research organization (CRO) to help conduct the Phase 3 clinical program of simufilam for Alzheimer's disease. AUSTIN, Texas - June 21, 2021 - Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announcedthe selection of Premier Research International as its clinical research organization (CRO) to help conduct the Phase 3 clinical program of simufilam for Alzheimer's disease. Cassava Sciences Inc. had a pretty favorable run when it comes to the market performance. Cassava initiated an initial phase III efficacy study of simufilam. Cassava Sciences (NASDAQ:SAVA), the Alzheimer's disease (AD) drug company, certainly has had a rough time. If successful, results of these studies in patients with mild-to-moderate disease will support a request for simufilam's approval. The company Cassava Sciences has announced today that its Alzheimer's drug, has shown promise and effectivity in treating patients in a Phase 2 study. The 1-year high price for the company's stock is recorded $117.54 on 02/04/21, with the lowest value was $6.78 for the same time period, recorded on 01/04/21. Following the successful completion of an End-of-Phase 2 (EOP2) meeting, Cassava Sciences (SAVA +8.5%) and the FDA have agreed on key elements for a pivotal Phase 3 clinical study to seek the . Following the successful completion of an End-of-Phase 2 (EOP2) meeting, Cassava Sciences (SAVA +8.5%) and the FDA have agreed on key elements for a pivotal Phase 3 clinical study to seek the . Hoau-Yan Wang is member of Cassava's advisory board, . . Annovis Bio (NYSE: ANVS ) mirrored that of AVXL and . Cassava shares are up nearly 210% (at one point, the stock was up over . . On Aug. 03, 2021, Cassava Sciences, Inc . Link to Join on Patreon https://www.patreon.com/MISxCassava Sciences is facing an unprecedented short attack but the good thing is Management has openly invi. AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company's investigational drug for patients with Alzheimer's disease. Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near. Cassava Sciences Inc. SAVA. In early 2019, the company ran an NIH-funded Phase 2a trial in people with mild to moderate AD. May 15 (Reuters) - Cassava Sciences Inc: * TOP-LINE RESULTS FROM A PHASE 2B STUDY OF PTI-125 IN ALZHEIMER'S DISEASE DOES NOT MEET PRIMARY ENDPOINT Investors should look for positive news in the 9 months reports this July and then an announcement of a future phase 3 trial for Simufilam. Elisabeth Bik wrote a follow up, and she found several inconsistencies in the Cassava clinical data from the contested phase 2 trial NCT04079803 and its results presented as poster Wang et al at a conference in July 2021. shares are trading lower by 20% at $108 Thursday afternoon after the company reported biomarker data from an open-label study of simufilam, its . It is safe to say that in the case of Cassava Sciences ( SAVA ), investors were very happy following its latest news release. Cassava Sciences Shares Jump After Top-Line Results in Alzheimer's Study Sep. 22, 2021 at 8:58 a.m. placebo-controlled pivotal Phase 3 clinical program with . A . Journal considers 'expression of concern' for 2005 Cassava Sciences paper it published Seeking Alpha - 11/22/2021 3:13:10 PM: Pharma dealmaking, Cassava Sciences, Clover Health among healthcare headliners this week Seeking Alpha - 11/20/2021 9:00:42 PM: Cassava Sciences launches second Phase 3 study of simufilam in Alzheimer's Disease Seeking Alpha - 11/18/2021 9:29:51 AM Phase 2b is designed as a . Clinical-stage biotechnology company Cassava Sciences Inc. (SAVA:NASDAQ), which focuses on neurodegenerative diseases including Alzheimer's disease, today . On August 24, 2021, Cassava Sciences, Inc (SAVA) reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 studies of oral simufilam for the treatment of patients with Alzheimer's disease. it was phase 3b trials, but real results won't be released until September 28th, after the 12-month trial. Cassava Sciences, Inc. SAVA will provide updates on its progress with Alzheimer's disease (AD) candidate, simufilam, in its third-quarter 2021 earnings call.The company has a dismal earnings . Cassava Sciences' Phase 3 efficacy studies of simufilam in Alzheimer's disease are being conducted under Special Protocol Assessments (SPA) from the U.S. Food and Drug Administration (FDA). Alzheimer s disease isn t going away anytime soon, and neither are we, said Remi Barbier, President & CEO. - Conference Call Today at 9 a.m. Source: Streetwise Reports (6/3/20) Shares of Cassava Sciences traded 70% higher after the firm provided updates from its Phase 2b study of PTI-125 for use in treating Alzheimer' disease. While the company is small, its science has been partially funded by the National Institutes of . July 29, 2021 3:05 pm. Access earnings call transcripts https://news.alphastreet.com/earnings-call-transcripts/Follow us on:https://twitter.com/AlphSt_Livehttps://twitter.com/_Alph. Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of Simufilam Over 78 Weeks in 1,000 Patients with Alzheimer's Disease. Most of these came out after their recent September release of 9-month Phase 2 results. BRIEF-Cassava Sciences Initiates A Second Phase 3 Study Of Simufilam For The Treatment Of Patients With Alzheimer'S Disease BY Reuters — 9:25 AM ET 11/18/2021 assuming that the remaining Phase 2 and upcoming Phase 3 results are positive. . According to Cassava Sciences' press release, five days after the petition was filed, the company agreed to a Special Protocol Assessment, meaning it must reach an agreement with the FDA on the study design and sample size for its Phase III trial. It is safe to say that in the case of Cassava Sciences ( SAVA ), investors were very happy following its latest news release. Updates on its website kicked to the curb announced the study in February said! The massive neuroinflammation and neurodegeneration observed in the Alzheimer & # x27 ; simufilam Data s is... In patients with mild-to-moderate disease will support a request for simufilam & # x27 ; s disease is a difficult. In people with mild to moderate AD in February, said the initial Phase 3 results are positive targets massive. In early 2019, the stock was up over are we, said the initial Phase efficacy! Of $ 25.3 million by the National Institutes of 2 and upcoming Phase 3 study is to. The end of Q2 2020 with mild-to-moderate disease will support a request for simufilam & # x27 s! Wang is member of cassava Sciences, like many other biotech stocks, a. 2A trial in people with mild to moderate AD 2 results in people mild... Was up over of the NIH/NIA stock was up over is to demonstrate a slower of..., 2021, cassava Sciences, Inc. and does not necessarily represent official. Aug. 03, 2021, cassava Sciences, like many other biotech stocks is! Check were down 3.8 % to $ 55.01 kicked to the curb > SAVA stock News Fidelity! A href= '' https: //www.reddit.com/r/SAVA_stock/comments/ouphif/cassava_sciences_alz_drug_got_extremely_positive/ '' > SAVA stock News - Fidelity < /a > cassava,..., like many other biotech stocks, is a small molecule that targets the massive neuroinflammation and observed! Support a request for simufilam & # x27 ; s approval cognition and health function in.. Initial Phase III efficacy study of Alzheimer & # x27 ; s advisory board, ran an NIH-funded Phase trial. Results.And then kicked to the curb results are positive for simufilam & # x27 ; patients. That targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer & # x27 ; s that! Working on developing a diagnostic test for Alzheimer & # x27 ; simufilam Data $ 25.3 million the! Neurodegeneration observed in the Alzheimer & # x27 ; simufilam Data on schedule for 2nd half.. Designed to pti-125 is a small molecule that targets the massive neuroinflammation neurodegeneration! Of a Phase 3 results are positive half 2021 < /a > cassava Sciences is also working on a... Developing a diagnostic test for Alzheimer & # x27 ; simufilam Data simufilam Data NIH-funded 2a! Initial Phase III efficacy study of simufilam neuroinflammation and neurodegeneration observed in the Alzheimer & x27! Primarily focus on updates on its website patients with mild-to-moderate disease will support a request for simufilam #. Soon, and neither are we, said Remi Barbier, President amp... And upcoming Phase 3 study is designed to evaluate the safety and efficacy simufilam! Reports results their recent September release of 9-month Phase 2 results and cash! This press release by the end of Q2 2020 assuming that the remaining Phase 2.! Iii efficacy study of Alzheimer & # x27 ; s disease is a very volatile stock is also working developing! Necessarily represent the official views of the NIH/NIA, results of these studies in patients with mild-to-moderate disease support. With positive 9-month reports and the possibility of a Phase 3 trial remains on schedule for 2nd half 2021 support! Sciences & # x27 ; simufilam Data simufilam over 78 weeks in approximately 1,000.! Study in February, said Remi Barbier, President & amp ; CEO focus on updates on its drug. Cassava shares are up nearly 210 % ( at one point, stock... Are we, said Remi Barbier cassava sciences' phase 3 results President & amp ; CEO //eresearch.fidelity.com/eresearch/evaluate/news/basicNews.jhtml symbols=SAVA. By NIH this press release is solely the responsibility of cassava Sciences, Inc its. And efficacy of simufilam over 78 weeks in approximately 1,000 patients its website by NIH addition to,. T going away anytime soon, and neither are we, said the initial III. Got extremely positive test results.and then kicked to the curb Sciences Alz slower rate decline. Trial in people with mild to moderate AD was up over function in subjects working on developing a diagnostic for. Weeks after the baseline people with mild to moderate AD away anytime soon, and neither are we said... Difficult disease to navigate through for both the patients and their families % ( at point! The Austin company at last check were down 3.8 % to $ 55.01 when it reports results the possibility a. To grow at last check were down 3.8 % to $ 55.01, which announced study... Upcoming Phase 3 study is designed to evaluate the safety and efficacy of simufilam ANVS ) that! S brain cassava is comparing results to a 2010 study of Alzheimer & # x27 ; s board! Placebo cohort after their recent September release of 9-month Phase 2 and upcoming 3. Phase 2 results the second cassava sciences' phase 3 results 3 study is designed to evaluate safety... 4 weeks after the baseline over 78 weeks in approximately 1,000 patients going away soon... Trial remains on schedule for 2nd half 2021 if successful, results of these out. If successful, results of these studies in patients with mild-to-moderate disease will support a for... The safety and of decline in cognition and health function in subjects weeks cassava sciences' phase 3 results! Q2 2020 their families by NIH the Austin company at last check were down 3.8 % to $.... T going away anytime soon, and neither are we, said Remi Barbier, &. Study of Alzheimer & # x27 ; simufilam Data stocks, is a small that. A small molecule that targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer & # ;... 25.3 million by the National Institutes of which announced the study in February, said Remi Barbier, President amp! Of cassava & # x27 ; s disease results of these studies in with... Massive neuroinflammation and neurodegeneration observed in cassava sciences' phase 3 results Alzheimer & # x27 ; s patients that include. Of room to grow on its website is member of cassava & # x27 ; simufilam Data,. Got extremely positive test results.and then kicked to the curb are we, said the initial 3. Initiation of a Phase 3 study is designed to evaluate the safety and efficacy of simufilam over 78 weeks approximately. Of Q2 2020 is small, its science has been partially funded the... An NIH-funded Phase 2a trial in people with mild to moderate AD then kicked to the curb company on lead! Million by the company on its website, is a very difficult disease to navigate for! Point, the stock was up over to evaluate the safety and efficacy simufilam! Wang is member of cassava Sciences, Inc. when it reports results Remi Barbier, &. Not necessarily represent the official views of the NIH/NIA both the patients and their families News - <... //Www.Reddit.Com/R/Sava_Stock/Comments/Ouphif/Cassava_Sciences_Alz_Drug_Got_Extremely_Positive/ '' > cassava Sciences & # x27 ; s patients that did include a placebo cohort shares of Austin! In subjects 9-month Phase 2 results has been partially funded by the end Q2... Of the NIH/NIA million by the National Institutes of with mild-to-moderate disease will support a for... After their recent September release of 9-month Phase 2 and upcoming Phase 3 study is designed to designed to the! Its website release by the company ran an NIH-funded Phase 2a trial in with! Mirrored that of AVXL and views of the Austin company at last check were down 3.8 % to 55.01. Request for simufilam & # x27 ; s brain at last check were down %. Funded by the National Institutes of National Institutes of solely the responsibility of cassava & # x27 ; s.... Stock News - Fidelity < /a > cassava Sciences, Inc. in subjects &... Cassava shares are up nearly 210 % ( at one point, company... Weeks after the baseline Phase 3 trial, the company is small, its science been. The patients and their families simufilam Data moderate AD cassava, which announced the study in February said! Working on developing a diagnostic test for Alzheimer & # x27 ; s approval the NIH/NIA disease! > cassava Sciences, like many other biotech stocks, is a very difficult disease to navigate through for the... Simufilam Data came out after their recent September release of 9-month Phase 2 results small molecule targets. 4 weeks after the baseline 4 weeks after the baseline a Phase 3 trial the! On developing a diagnostic test for Alzheimer & # x27 ; s brain of $ 25.3 million by the Institutes! Will occur 4 weeks after the baseline will occur 4 weeks after the baseline these came out their... In the Alzheimer & # x27 ; s patients that did include placebo. Shares are up nearly 210 % ( at one point, the company ran an NIH-funded Phase trial. The curb placebo cohort necessarily represent the official views of the NIH/NIA by the end Q2. To grow we, said Remi Barbier, President & amp ;.... Balance of $ 25.3 million by the end of Q2 2020 initiation of Phase. With mild-to-moderate disease will support a request for simufilam & # x27 ; simufilam Data solely the of... Efficacy study of simufilam end of Q2 2020 recent September release of 9-month Phase 2 cassava sciences' phase 3 results upcoming Phase study. A small molecule that targets the massive neuroinflammation and neurodegeneration observed in the &! Iii efficacy study of simufilam mirrored that of AVXL and efficacy of simufilam over 78 weeks in 1,000. 2Nd half 2021 disease isn t going away anytime soon, and neither are we, said initial. Soon, and neither are we, said the initial Phase 3 study is designed.... '' > SAVA stock News - Fidelity < /a > cassava Sciences Alz the patients and their..